



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Yong KWEE et al.

Title:

HM1.24-UTILIZING CANCER VACCINES

Appl. No.:

10/533,104

Filing Date:

04/28/2005

Examiner:

Unassigned

Art Unit:

1645

Confirmation No.:

5920

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of a document known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

This Information Disclosure Statement is also being filed to supplement the IDS previously submitted to the US Patent and Trademark Office on April 28, 2005.

Applicants would like to reference the Notice of Acceptance of Application under 35 USC 371, mailed March 24, 2006. The Notice does not indicate that a copy of the references have been provided from the International Bureau, therefore, Applicants provide herewith a copy of the references (Documents A1- A11) which were cited in the International Search Report, in compliance with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the

present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits, and within three (3) months of the mailing date of the foreign search report.

RELEVANCE OF EACH DOCUMENT

All of the documents listed on the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding European application. A copy of the Supplementary European Search Report is attached setting forth the portion of each document considered relevant by the examiner.

Applicant respectfully requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date June 23, 2006

FOLEY & LARDNER LLP Customer Number: 22428

Facsimile:

Telephone: (202) 672-5569

(202) 672-5399

Stephen B. Maebius Attorney for Applicant

By Reg. No. 32, 904, for

Registration No. 35,264

OTP F RE

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwood Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known 10/533,104 INFORMATION DISCLOSURE **Application Number** 04/28/2005 STATEMENT BY APPLICANT **Filing Date** Yong KWEE **First Named Inventor** Date Submitted: June 23, 2006 Group Art Unit 1645 (use as many sheets as necessary) **Examiner Name** Unassigned 053466-0401 1 of | 1 Attorney Docket Number Sheet

				U.S. PATENT DOCUMENTS	;	
Examiner Initials*	-	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
			+			

Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]
	B1	EP	1 059 533	A1	Chugai Seiyaku Kabushiki Kaisha	12/13/2000		

	***	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B2	HUNDEMER et al., "Identification of T Cell Epitopes within the Plasmacell Antigen HM1.24", 2002, Blood, Vol. 100, No. 11, pg. Abstract No. 5088, XP009063835.	
	В3	NICOLA DI et al., "Gene Transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors", 1998, Cancer Gene Therapy, Vol. 5, No. 6, pgs. 350-356.	
	B4	OHTOMO et al., "Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma Cells", Biochemical and Biophysical Research Communications, 1999, Vol. 258, No. 3, pgs. 583-591.	
	B5	OZAKI et al., "Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That is Enhanced by Cytokine Stimulation of Effector Cells", Blood, 1999, Vol. 93, No. 11, pgs. 3922-3930.	
	B6	REW, et al, "Potent anti-tumour cytotoxic T lymphocytes directed against the myloma antigen HM1.24", Blood, 2003, Vol. 102, No. 11, pg. 112A, XP009063769.	

Examiner Signature		Date Consid	ered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.